Cancer-Related Fatigue: Why Rest Isn’t Always Enough

Cancer-Related Fatigue: Why Rest Isn’t Always Enough

Cancer-related fatigue is more than feeling tired after a busy day. It is a persistent sense of physical, emotional, or mental exhaustion that can interfere with everyday activities and may not improve with sleep or rest. For people living with cancer, understanding what causes this fatigue and how to manage it can make an important difference in quality of life.

What Makes Cancer-Related Fatigue Different from Everyday Tiredness?

Unlike typical tiredness, cancer-related fatigue may feel overwhelming even after a full night of sleep. It can make simple activities, such as preparing meals, taking a walk, or concentrating on a conversation, feel unusually difficult.

Some people experience physical weakness, while others notice difficulty concentrating, reduced motivation, or emotional exhaustion. Fatigue can vary from day to day and may continue after treatment has ended.

Why Does Cancer Cause Fatigue?

Cancer-related fatigue can have several contributing factors, including the cancer itself, its treatments, and other physical or emotional changes.

Common contributors include:

  • Cancer treatments: Chemotherapy, radiation therapy, immunotherapy, and other treatments may contribute to fatigue.
  • Anemia: A low red blood cell count can reduce the body’s ability to carry oxygen, contributing to weakness and tiredness.
  • Changes in nutrition: Reduced appetite, difficulty eating, or inadequate fluid intake may affect energy levels.
  • Sleep disturbances: Pain, stress, medications, or changes in routine may interfere with restful sleep.
  • Emotional health: Anxiety, depression, and the emotional demands of a cancer diagnosis can contribute to fatigue.

Often, more than one factor is involved. Identifying possible contributors can help a care team recommend appropriate strategies.

Why Doesn’t More Sleep Always Help?

Cancer-related fatigue is not always caused by a lack of sleep. Because it can involve treatment effects, inflammation, anemia, and other underlying factors, additional rest alone may not resolve it.

While adequate sleep is important, spending more time in bed does not necessarily improve energy levels. For some patients, long periods of inactivity may contribute to muscle weakness and reduced endurance.

Finding the right balance between rest and activity can be an important part of managing fatigue.

What Can Help Manage Cancer-Related Fatigue?

Although there is no single solution that works for everyone, several strategies may help improve energy and daily functioning.

  1. Consider gentle physical activity. When approved by your care team, activities such as walking, stretching, or other appropriate movement may help reduce fatigue over time. The right level of activity depends on your health, treatment, and physical abilities.
  2. Prioritize your energy. Plan important activities for times of day when you typically feel your best. Break larger tasks into smaller steps and allow yourself to ask for help.
  3. Maintain consistent sleep habits. Try to follow a regular sleep schedule and create a comfortable sleep environment. Talk with your care team if sleep difficulties continue.
  4. Support your nutritional needs. Eating regularly and staying hydrated may help support your overall health. A registered dietitian can provide guidance if treatment affects your appetite or ability to eat.
  5. Discuss symptoms with your care team. Fatigue may be related to treatable conditions, such as anemia, pain, medication side effects, or sleep problems. Your care team can help identify potential causes and recommend supportive care.

When Should You Talk to Your Cancer Care Team About Fatigue?

Tell your care team if fatigue is persistent, worsening, or interfering with everyday activities. You do not need to wait until exhaustion becomes severe to bring it up.

It may help to track when fatigue occurs, how long it lasts, and what activities are most affected. Sharing these details can help your care team better understand your symptoms.

Seek prompt medical guidance for sudden or significant changes in energy, particularly when accompanied by new or concerning symptoms. Severe shortness of breath, chest pain, or fainting require emergency medical attention.

Managing Fatigue Is Part of Cancer Care

Cancer-related fatigue is common, but that does not mean patients must simply accept it without support. Understanding its possible causes and discussing symptoms with your care team can help identify ways to improve comfort, daily functioning, and quality of life.

Questions about your treatment schedule? Contact our office directly at 843-790-8280 or speak with your care coordinator.

 

Why Pancreatic Cancer Can Be Hard to Detect Early

Why Pancreatic Cancer Can Be Hard to Detect Early

Pancreatic cancer can be difficult to detect early because it often develops without noticeable symptoms, and there is no recommended routine screening test for people at average risk. Unlike some other cancers, pancreatic cancer may go undetected until it has grown or spread beyond the pancreas.

Understanding why early detection is challenging, recognizing potential warning signs, and knowing when to discuss personal risk factors with a healthcare provider can help individuals make informed decisions about their health.

Why Is Pancreatic Cancer Difficult to Detect in Its Early Stages?

Several factors make pancreatic cancer particularly challenging to identify before symptoms develop.

  • The pancreas is located deep within the abdomen. Unlike certain other organs, the pancreas cannot easily be examined for abnormalities during a routine physical exam. Small tumors may develop without being seen or felt.
  • Early symptoms are often absent or difficult to recognize. Pancreatic cancer may not cause noticeable changes until the disease has progressed. When symptoms do appear, they can resemble those of more common, less serious conditions.
  • Routine screening is not recommended for everyone. Unlike breast or colorectal cancer, pancreatic cancer does not have an established routine screening program for people at average risk.

Together, these challenges can make early diagnosis difficult, even when individuals are attentive to their health.

What Are Some Early Warning Signs of Pancreatic Cancer?

Although pancreatic cancer often causes no symptoms in its early stages, certain changes may warrant medical evaluation.

Potential symptoms include:

  • Persistent abdominal or back pain: Discomfort may develop in the upper abdomen or extend into the back.
  • Unexplained weight loss: Losing weight without changes to diet or physical activity may be a warning sign.
  • Jaundice: Yellowing of the skin or whites of the eyes, sometimes accompanied by dark urine, pale stools, or itching.
  • Changes in appetite or digestion: Reduced appetite, nausea, or digestive discomfort may occur.
  • Unusual fatigue: Persistent weakness or exhaustion without a clear explanation.
  • New-onset diabetes: In some cases, a new diabetes diagnosis, particularly later in adulthood and without typical risk factors, may warrant further evaluation.

These symptoms are much more commonly associated with conditions other than pancreatic cancer. However, persistent, unexplained, or worsening changes should be discussed with a healthcare provider. New jaundice should be evaluated promptly.

Who May Be at Increased Risk for Pancreatic Cancer?

While pancreatic cancer can develop without identifiable risk factors, certain characteristics may increase a person’s likelihood of developing the disease.

These include:

  • Family history: Having close relatives diagnosed with pancreatic cancer may increase risk.
  • Inherited genetic changes: Certain inherited mutations, including some involving the BRCA1, BRCA2, PALB2, and CDKN2A genes, are associated with increased risk.
  • Smoking: Tobacco use is an established risk factor for pancreatic cancer.
  • Chronic pancreatitis: Long-term inflammation of the pancreas may increase risk.
  • Age: Pancreatic cancer becomes more common with increasing age.
  • Heavy alcohol use: Heavy alcohol consumption may increase the risk of pancreatic cancer, particularly through its association with chronic pancreatitis.
  • Other health factors: Obesity and diabetes are also associated with pancreatic cancer risk.

Having one or more risk factors does not mean someone will develop pancreatic cancer. However, understanding personal and family medical history can help guide conversations about whether additional evaluation or genetic counseling may be appropriate.

Is There a Screening Test for Pancreatic Cancer?

Currently, routine pancreatic cancer screening is not recommended for people at average risk. Researchers continue to investigate blood tests, imaging methods, and other approaches that may help identify pancreatic cancer earlier.

For certain individuals at increased risk, specialized screening or surveillance may be recommended.

Depending on personal and family history, healthcare providers may consider:

  • Magnetic resonance imaging (MRI) or magnetic resonance cholangiopancreatography (MRCP): Imaging techniques that provide detailed views of the pancreas and surrounding structures.
  • Endoscopic ultrasound (EUS): A procedure that uses ultrasound technology to examine the pancreas from within the digestive tract.
  • Genetic counseling and testing: Services that may help identify inherited cancer risks and guide screening decisions.

These approaches are generally reserved for individuals who meet specific high-risk criteria and should be discussed with a qualified healthcare provider.

When Should You Talk to Your Doctor About Pancreatic Cancer Risk?

You do not need to wait for symptoms to begin a conversation about your risk.

Consider speaking with your healthcare provider if you have a significant family history of pancreatic cancer, a known inherited cancer-related genetic mutation, or persistent symptoms that do not have a clear explanation.

Your provider can review your medical history, assess potential risk factors, and determine whether further evaluation or referral to a specialist is appropriate.

Why Awareness and Early Detection Research Matter

Pancreatic cancer remains challenging to detect in its earliest stages, but research is advancing our understanding of the disease and potential methods for earlier diagnosis.

Recognizing concerning symptoms, understanding inherited risk, and discussing changes with a healthcare provider are important steps toward informed, proactive care.

During Pancreatic Cancer Awareness Month and throughout the year, education can help individuals better understand their health and know when to seek medical guidance.

Questions about your treatment schedule? Contact our office directly at 843-790-8280 or speak with your care coordinator.

Lung Cancer: Why Your Treatment Plan May Look Different From Someone Else’s

Lung Cancer: Why Your Treatment Plan May Look Different From Someone Else’s

A lung cancer treatment plan is not the same for every patient. Even two people diagnosed with lung cancer at a similar time may receive very different recommendations based on the type and stage of their cancer, certain characteristics of their tumor, and their overall health.

Understanding what goes into a lung cancer treatment plan can help patients feel more informed about their care and the questions they may want to ask their oncology team.

Why Do Lung Cancer Treatments Differ Between Patients?

Lung cancer is not a single disease, and treatment decisions involve more than the diagnosis alone.

An oncology team considers several factors when recommending treatment, including the type of lung cancer, how far it has spread, whether certain biomarkers, including specific genetic mutations, are present, which treatments the patient has previously received, and the patient’s overall health and treatment goals.

This means that a treatment recommended for one person may not be appropriate for another, even if both have been diagnosed with lung cancer.

How Does the Type of Lung Cancer Affect Treatment?

The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Non-small cell lung cancer (NSCLC) is the more common type and includes subtypes such as adenocarcinoma and squamous cell carcinoma. Depending on the stage and other factors, treatment may involve surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of approaches.

Small cell lung cancer (SCLC) generally grows and spreads more quickly. Treatment often involves systemic therapies, such as chemotherapy and immunotherapy, sometimes combined with radiation therapy.

Identifying the specific type of lung cancer is one of the first steps in determining an appropriate treatment approach.

Why Does the Stage of Lung Cancer Matter?

Cancer stage describes the extent of cancer in the body, including the size and location of the tumor and whether it has spread to lymph nodes or other organs.

For some patients with early-stage lung cancer, surgery or radiation therapy may be recommended with the goal of treating the cancer locally. Other treatments may also be recommended to reduce the risk of recurrence.

For patients with more advanced disease, treatment may focus on controlling cancer throughout the body, managing symptoms, and maintaining quality of life.

The stage of cancer helps guide treatment recommendations, but it is only one part of the decision-making process.

What Is Biomarker Testing, and How Can It Influence Treatment?

Biomarker testing looks for certain molecular characteristics of cancer cells that may help guide treatment decisions.

In some types of non-small cell lung cancer, testing may identify changes in genes such as EGFR, ALK, ROS1, or other biomarkers that can help determine whether targeted therapy may be an option.

Other tests, such as PD-L1 testing, may provide information that helps the oncology team consider immunotherapy.

Not every patient will have an actionable biomarker, and testing recommendations depend on the type and stage of lung cancer. However, when appropriate, biomarker testing can provide important information for developing an individualized treatment plan.

How Do Overall Health and Personal Preferences Affect Treatment?

Cancer treatment decisions also consider the person receiving care, not just the cancer itself.

A patient’s overall health, other medical conditions, lung function, and ability to tolerate certain treatments may influence which options are recommended.

Personal preferences and treatment goals are also important. Patients may have questions about potential side effects, treatment schedules, daily activities, and how treatment could affect their quality of life.

Discussing these priorities with an oncology team supports shared decision-making and helps ensure the treatment plan reflects each patient’s individual circumstances.

Can a Lung Cancer Treatment Plan Change Over Time?

Yes. A lung cancer treatment plan may change based on how the cancer responds, new test results, side effects, or changes in a patient’s health.

For example, a treatment may be adjusted if it is not working as expected or if side effects become difficult to manage. In certain circumstances, additional biomarker testing may help identify other treatment options.

Regular communication and follow-up appointments allow the oncology team to evaluate progress and determine whether changes are needed.

What Questions Should You Ask About Your Lung Cancer Treatment Plan?

Understanding the reasons behind a treatment recommendation can help patients participate more confidently in decisions about their care.

Consider asking your oncology team:

  • What type and stage of lung cancer do I have?
  • Is biomarker testing recommended for my diagnosis?
  • What treatment options are available, and why are you recommending this approach?
  • What are the goals and potential side effects of treatment?
  • How will we know whether my treatment is working?
  • Are clinical trials an option for me?

Personalized Care Starts With Understanding Your Options

There is no single treatment plan that is right for everyone diagnosed with lung cancer. Advances in cancer research and treatment have expanded the options available to certain patients, allowing oncology teams to consider more characteristics of both the cancer and the individual.

Understanding the factors behind treatment recommendations and maintaining open communication with your care team can help you make informed decisions throughout your cancer care journey.

Five Common Misconceptions About Cancer Clinical Trials

Five Common Misconceptions About Cancer Clinical Trials

Cancer clinical trials play an important role in advancing cancer care and may also be a treatment option for eligible patients. However, misconceptions about how they work can make patients hesitant to consider participating. Clinical trials help researchers evaluate new treatments, new combinations of existing treatments and other approaches that may eventually become part of standard cancer care.

For patients, however, the words “clinical trial” can sometimes bring uncertainty. Will I receive a placebo? Does participating mean there are no other treatment options? Will I be treated like a test subject?

Understanding what clinical trials actually involve can help patients and their families have more informed conversations with their care teams.

Misconception #1: Clinical Trials Are Only a Last Resort

Do you have to run out of treatment options before considering a clinical trial? No. Clinical trials are available for people at different stages of cancer, including some patients who have been newly diagnosed. There are also studies focused on cancer prevention, screening, supportive care and survivorship.

Whether a particular trial is appropriate depends on its eligibility requirements. These can include the type and stage of cancer, previous treatments, overall health, age and specific characteristics of the tumor.

For some patients, discussing clinical trials earlier in the treatment-planning process may provide additional options to consider alongside standard treatments.

Misconception #2: Everyone in a Clinical Trial Receives an Experimental Treatment

Clinical trials are carefully designed research studies, and the treatment a participant receives depends on the specific trial.

Some cancer treatment trials compare a new approach with the current standard treatment. Others may study a new treatment in combination with an established therapy or evaluate a different way of using an existing treatment.

Before joining a study, patients go through an informed consent process that explains the purpose of the trial, the treatments or procedures involved, potential risks and benefits and what participation will require.

Misconception #3: You Might Get a Placebo Instead of Cancer Treatment

Placebos are rarely used by themselves in cancer treatment clinical trials when an effective standard treatment is available. It would generally be unethical to withhold an established effective treatment simply for the purpose of comparison.

When a placebo is used, it may be in a study comparing:

Standard treatment + investigational treatment

with

Standard treatment + placebo

Placebos may also be used when there is no standard treatment available. If a clinical trial involves a placebo, patients are told about that possibility during the informed consent process before deciding whether to participate.

Misconception #4: Clinical Trials Are Not as Safe as Standard Cancer Care

Clinical trials involve uncertainty because researchers are still studying the treatment or approach. Participation can carry risks, including unexpected side effects or the possibility that a new treatment will not work as well as standard treatment.

However, clinical trials are conducted under established safeguards designed to protect participants.

Depending on the study, protections can include scientific review, review by an Institutional Review Board (IRB), a detailed study protocol, informed consent and ongoing safety monitoring. Participants are also closely monitored by the research team throughout the study.

Importantly, informed consent is an ongoing process. Participants can ask questions throughout the study and may choose to leave a clinical trial at any time.

Misconception #5: Participating in a Clinical Trial Only Helps Future Patients

Clinical trials are essential to improving cancer care for future patients, but participation may also offer potential benefits to the person enrolled.

Depending on the study, participants may have access to a treatment under investigation that is not otherwise available. They are also closely followed by the research team throughout participation. However, there is no guarantee that an investigational treatment will work or be better than the current standard of care.

For many participants, contributing to knowledge that may improve cancer prevention, diagnosis or treatment for others is another meaningful reason to consider research.

 

What Should You Ask Before Joining a Clinical Trial?

Deciding whether to participate in a clinical trial is a personal decision. Patients should have an opportunity to understand the study and consider how participation fits with their treatment goals and daily lives.

Questions to ask your doctor or research team may include:

  • What is the purpose of this clinical trial?
  • Why might this trial be appropriate for me?
  • What treatment would I receive?
  • How does this compare with my standard treatment options?
  • What are the possible risks and benefits?
  • How often would I need appointments, tests or procedures?
  • What costs are covered by the study, and what might my insurance cover?
  • How could participation affect my daily routine?
  • What happens if I decide I no longer want to participate?

These conversations are an important part of informed consent and can help patients decide whether participation is right for them.

Why Cancer Clinical Trials Matter

Nearly every advancement in cancer care depends on research to determine whether new approaches are safe and effective. Clinical trials provide the evidence needed to move promising discoveries from research settings into everyday cancer care.

Participating in a clinical trial is not the right choice for every patient, and not every patient will qualify for every study. But understanding the facts can help ensure that misconceptions do not prevent someone from asking about an option that may be appropriate for them.

If you are interested in cancer clinical trials, talk with your care team about studies that may be available for your cancer type and whether participating in research could be part of your treatment plan.

 

 

 

 

 

 

 

CAR-T Therapy and Community Oncology: What Expanded Access Means for Patients

CAR-T Therapy and Community Oncology: What Expanded Access Means for Patients

Not long ago, CAR-T cell therapy was available only at a handful of major academic medical centers. For patients who needed it, that often meant traveling far from home, staying near a treatment facility for weeks, and navigating a system that felt distant from the community-based care they were used to. For many, logistics alone were a barrier.

That picture has changed significantly. CAR-T therapy is reaching more patients, in more places, than ever before. And for patients treated within community oncology practices like Lowcountry Oncology Associates, that shift has real, practical meaning.

What CAR-T Therapy Is

CAR-T stands for chimeric antigen receptor T-cell therapy. It is a form of immunotherapy in which a patient’s own T-cells, a type of immune cell, are collected, genetically modified in a laboratory to recognize and attack cancer cells, and then infused back into the patient.

It is not a standard chemotherapy. It is not a targeted drug. It is a living therapy, engineered from the patient’s own biology, designed to seek out and destroy cancer cells in a way that conventional treatments cannot.

CAR-T has been approved by the FDA for several blood cancers, including certain types of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. Research into its use in other cancers, including solid tumors, is actively ongoing.

For patients with certain relapsed or refractory blood cancers, CAR-T therapy has produced remissions in cases where other treatments had stopped working. That is not a small thing.

Why Access Was Limited, and What Has Changed

The early years of CAR-T were defined by complexity. Manufacturing the therapy requires sophisticated cell processing facilities. Administering it requires close monitoring for serious side effects, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), both of which can be severe and require prompt intervention. The infrastructure demands were significant, and only a small number of certified centers were equipped to meet them.

Over time, that has changed. The number of authorized treatment centers has grown substantially. CAR-T manufacturers have invested in expanding the network of certified sites. Outcomes data has informed better protocols for managing side effects. And the oncology community has developed a deeper collective experience with the therapy that has made administration safer and more predictable.

Community oncology has played a growing role in this expansion. While not every community practice administers CAR-T directly, the integration of community oncology into the broader CAR-T care continuum has meaningfully improved the patient experience. Community oncologists are increasingly involved in identifying appropriate candidates early, coordinating referrals efficiently, managing patients before and after CAR-T, and serving as the ongoing care relationship that academic centers often cannot provide long-term.

What This Means for Patients

For a patient being treated at Lowcountry Oncology Associates, expanded CAR-T access means several things in practice.

It means that if CAR-T may be appropriate for your diagnosis, the conversation can start here. Your care team knows what to look for, understands the eligibility criteria, and can initiate the evaluation process without you having to find your way to a CAR-T center on your own.

It means that the relationship with your team does not end if you receive CAR-T elsewhere. Long-term follow-up, monitoring for late effects, and ongoing cancer management can continue close to home, with a team that knows you.

And it means that you do not have to figure any of this out alone. If CAR-T comes up as a possibility in your treatment, your care coordinator at Lowcountry Oncology Associates is the right first call.

Who May Be a Candidate

CAR-T is not appropriate for every patient or every diagnosis. It is typically considered for patients with specific blood cancers that have relapsed or have not responded to prior lines of therapy. Eligibility depends on the type and subtype of cancer, prior treatment history, the patient’s overall health and organ function, and other clinical factors.

The evaluation process is thorough, and not every patient who is referred will ultimately proceed to CAR-T. That is not a failure. It means the process is working as it should, identifying the patients most likely to benefit and ensuring the risks are appropriate for each individual situation.

If you have questions about whether CAR-T could be relevant to your diagnosis, the right starting point is a conversation with your oncologist at Lowcountry Oncology Associates. We can review your specific situation, discuss what the evidence shows for your cancer type, and help you understand all of your options.

What the Process Looks Like

For patients who do move forward with CAR-T, understanding the process helps reduce some of the uncertainty. In broad terms, it involves several phases.

First, a patient’s T-cells are collected through a process called leukapheresis, in which blood is drawn, the T-cells are separated out, and the remaining blood is returned to the patient. The collected cells are then sent to a manufacturing facility where they are genetically engineered, a process that typically takes several weeks.

While the cells are being manufactured, patients may receive bridging therapy to help keep their cancer stable. When the engineered cells are ready, the patient receives a short course of lymphodepleting chemotherapy followed by the CAR-T infusion itself.

After infusion, patients are monitored closely, typically for at least several weeks near the treatment center, for side effects including CRS and ICANS. Once cleared, ongoing follow-up continues, often in partnership with their community oncology team.

It is a significant undertaking. But for patients for whom it works, the outcomes can be profound.

The Role of Lowcountry Oncology Associates in Your CAR-T Journey

Whether CAR-T is a current consideration or something that may become relevant down the road, your [Practice Name] team is here to help you stay informed and navigate your options.

Community oncology is not a lesser version of cancer care. It is cancer care that knows you, stays with you, and advocates for you throughout the entire arc of your treatment, including when that treatment takes you somewhere else for a time.

If you have questions about CAR-T therapy and whether it may be relevant to your diagnosis, start the conversation with your care team at Lowcountry Oncology Associates. That is exactly what we are here for.

 

 

 

Liver Cancer Is Often Silent: Why Regular Monitoring Matters for Those at Higher Risk

Liver Cancer Is Often Silent: Why Regular Monitoring Matters for Those at Higher Risk

Liver cancer surveillance can help detect cancer earlier in people who are at higher risk, often before noticeable symptoms develop. Unlike some cancers that may cause warning signs in their early stages, liver cancer can develop quietly. Symptoms may not appear until the disease has progressed, which is one reason regular monitoring can be important for certain people with chronic liver disease or other risk factors.

Liver Cancer Awareness Month is an opportunity to understand not only the disease itself, but also who may be at increased risk and when regular surveillance may be appropriate. Knowing your personal risk factors and talking with your healthcare provider can help determine whether ongoing monitoring should be part of your care.

Why Can Liver Cancer Be Difficult to Detect Early?

Liver cancer may not cause noticeable symptoms during its early stages. When symptoms do develop, they can include abdominal discomfort or swelling, unexplained weight loss, loss of appetite, fatigue, nausea or yellowing of the skin and eyes, known as jaundice.

Because symptoms can appear later in the disease, waiting until something feels wrong may not be the best approach for people who already have a higher risk of developing liver cancer. The American Cancer Society notes that there are no widely recommended liver cancer screening tests for people at average risk, but regular testing may be recommended for certain people at higher risk.

This distinction is important: surveillance is not recommended for everyone. It is intended for people whose individual risk is high enough that regular monitoring may provide a benefit.

Who Is at Higher Risk for Liver Cancer?

Hepatocellular carcinoma, or HCC, is the most common type of primary liver cancer in adults and often develops in people who have chronic liver disease. Cirrhosis and chronic viral hepatitis are among the most significant risk factors.

People who may have an increased risk include those with:

  • Cirrhosis: Long-term liver damage can cause healthy liver tissue to be replaced with scar tissue. Cirrhosis can result from several conditions and significantly increases the risk of liver cancer.
  • Chronic hepatitis B: Long-term infection with hepatitis B virus can increase liver cancer risk, including in some people who have not developed cirrhosis.
  • Chronic hepatitis C: Hepatitis C can cause ongoing liver inflammation and damage that may eventually lead to cirrhosis and increase liver cancer risk.
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): Previously known as nonalcoholic fatty liver disease, MASLD can progress in some people to metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH, fibrosis and cirrhosis. Advanced liver disease related to MASLD/MASH can increase liver cancer risk.
  • Certain inherited or chronic liver conditions: Conditions such as hereditary hemochromatosis and some autoimmune or metabolic liver diseases can lead to cirrhosis and increase liver cancer risk.

Having one of these conditions does not mean someone will develop liver cancer, and surveillance recommendations are not identical for everyone with a risk factor.

What Does Liver Cancer Surveillance Involve?

For people who meet criteria for liver cancer surveillance, regular testing allows healthcare providers to look for changes in the liver before symptoms develop.

Current American Association for the Study of Liver Diseases guidance recommends liver cancer surveillance approximately every six months using abdominal ultrasound and an alpha-fetoprotein (AFP) blood test for people with cirrhosis and certain populations with chronic hepatitis B.

An ultrasound uses sound waves to create images of the liver and can help identify suspicious areas or changes.

An AFP blood test measures alpha-fetoprotein, a substance that can be elevated in some people with liver cancer. AFP is not a perfect test and can be elevated for reasons other than cancer. Some people with liver cancer may also have normal AFP levels, which is why it is not used alone to diagnose the disease.

If surveillance identifies something unusual, additional imaging or testing may be recommended.

Why Does Early Detection Matter?

Finding liver cancer at an earlier stage can create more opportunities for potentially curative treatment.

Depending on the cancer and the health of the liver, early-stage treatment options can include surgery to remove part of the liver, liver transplantation or local treatments such as ablation. Treatment decisions depend on many factors, including the size and location of the cancer, how well the liver is functioning and the patient’s overall health.

This is why surveillance can be especially valuable for people known to be at higher risk. The goal is to identify concerning changes when the cancer may still be small and more treatment options may be available.

Should You Be Screened for Liver Cancer?

There is no routine liver cancer screening recommendation for everyone. Whether surveillance is appropriate depends on a person’s underlying liver disease, medical history and individual level of risk.

If you have cirrhosis, chronic hepatitis B or C, advanced liver disease related to MASLD/MASH, an inherited liver condition or another history of chronic liver disease, talk with your healthcare provider about your individual risk.

Questions you may want to ask include:

  • Am I at increased risk for liver cancer?
  • Should I undergo regular liver cancer surveillance?
  • How often should I be monitored?
  • What tests are appropriate for me?
  • Are there steps I can take to protect my liver health?

Your healthcare provider can consider your complete medical history and help determine whether regular surveillance is appropriate.

Staying Ahead of a Disease That May Not Cause Early Symptoms

Liver Cancer Awareness Month is a reminder that awareness is not limited to recognizing symptoms. For people at increased risk, knowing whether regular surveillance is appropriate can be equally important.

Liver cancer may develop without obvious early warning signs, but identifying it earlier can provide more treatment options. If you have a history of chronic liver disease or other liver cancer risk factors, talk with your healthcare provider about your risk and whether ongoing monitoring should be part of your care.